Norovirus is a very contagious virus (infection) sometimes referred to as a “stomach bug”. Norovirus commonly causes vomiting, diarrhea, sudden nausea (the feeling of wanting to vomit), and stomach cramps. It may also cause fever, headache and body aches. This research study is comparing two potential new vaccines to prevent healthy adults from getting sick from norovirus. Both vaccines are made of two vaccine parts.
The purpose of this study is to compare 2 different study vaccine doses by evaluating immune system responses (the body’s defense system) and reactions after the study vaccinations. In addition, this study will compare the reactions following the vaccination with the MVA‑BN‑WEV study vaccine or placebo.
The purpose of this phase 2 clinical trial is to better understand the effects of different specific features of mRNA-1083 (the trial vaccine).
The purpose of this research is to assess the safety and efficacy of IMM01-STEM in senior participants with muscle weakness and obesity (Sarcopenic Obesity).
Researchers are testing an oral SARS-COV-2 vaccine tablet to see if this experimental vaccine will help in the prevention of COVID-19 infection or symptoms due to COVID-19 infection. This study will also evaluate how well people tolerate taking the study vaccine.
You are invited to take part in this clinical trial because currently, there is no approved vaccine for the prevention of acute gastroenteritis (AGE) caused by norovirus. Acute gastroenteritis, commonly known as the stomach flu or stomach bug, is characterized by symptoms such as nausea, vomiting, diarrhea, abdominal cramps, and sometimes fever. The purpose of this clinical trial is to evaluate an investigational vaccine to prevent AGE caused by a norovirus infection.
We are doing this research trial to find out more about an investigational vaccine called mRNA-1189 that is being tested to see if it gives protection from a virus called Epstein-Bar Virus, or EBV for short. EBV is a very common virus that is spread from person to person by close contact beginning in childhood. By age 24, about 90% of people will have already had an EBV infection, however most people show no symptoms. EBV is also the main cause of an illness called infectious mononucleosis (IM), or “mono” for short.
